Traditional Chinese Medicine in the Management of Colorectal Cancer Liver Metastasis: Mechanisms, Challenges, and Perspectives.
[BACKGROUND] Colorectal cancer (CRC) is one of the most common malignancies worldwide, and the liver is its main site of distant metastasis.
APA
Li N, Liu L, et al. (2026). Traditional Chinese Medicine in the Management of Colorectal Cancer Liver Metastasis: Mechanisms, Challenges, and Perspectives.. Pharmacology, 111(1), 33-49. https://doi.org/10.1159/000549133
MLA
Li N, et al.. "Traditional Chinese Medicine in the Management of Colorectal Cancer Liver Metastasis: Mechanisms, Challenges, and Perspectives.." Pharmacology, vol. 111, no. 1, 2026, pp. 33-49.
PMID
41248113
Abstract
[BACKGROUND] Colorectal cancer (CRC) is one of the most common malignancies worldwide, and the liver is its main site of distant metastasis. Colorectal cancer liver metastasis (CRLM) is a major cause of CRC-related death. Current treatments, including surgery, chemotherapy, and immunotherapy, have limited efficacy and often cause substantial side effects.
[SUMMARY] This review examines the emerging role of traditional Chinese medicine (TCM) in managing CRLM, focusing on its ability to modulate the tumor microenvironment (TME) by inhibiting epithelial-mesenchymal transition, suppressing angiogenesis, and reversing immune evasion. TCM provides a holistic, multi-targeted approach, but most supporting evidence comes from preclinical studies in cell and animal models, with limited clinical validation.
[KEY MESSAGES] TCM shows promise for targeting the CRLM-related TME. Most evidence is preclinical; well-designed clinical trials are urgently needed. Standardization, pharmacokinetics, and regulatory issues remain major barriers to clinical application.
[SUMMARY] This review examines the emerging role of traditional Chinese medicine (TCM) in managing CRLM, focusing on its ability to modulate the tumor microenvironment (TME) by inhibiting epithelial-mesenchymal transition, suppressing angiogenesis, and reversing immune evasion. TCM provides a holistic, multi-targeted approach, but most supporting evidence comes from preclinical studies in cell and animal models, with limited clinical validation.
[KEY MESSAGES] TCM shows promise for targeting the CRLM-related TME. Most evidence is preclinical; well-designed clinical trials are urgently needed. Standardization, pharmacokinetics, and regulatory issues remain major barriers to clinical application.
MeSH Terms
Humans; Colorectal Neoplasms; Liver Neoplasms; Medicine, Chinese Traditional; Animals; Tumor Microenvironment; Drugs, Chinese Herbal; Epithelial-Mesenchymal Transition
같은 제1저자의 인용 많은 논문 (5)
- GSTM2 as the molecular linking of depression-driven colon cancer progression and chemoresistance: Reversal by Sinisan.
- Targeting LRPPRC lactylation disrupts metabolic-immune crosstalk and restores antitumor immunity in hepatocellular carcinoma.
- Neoadjuvant Immunochemotherapy Increases the Abundance of Tertiary Lymphoid Structures and Lymphocyte Subpopulations Is Associated With Prognosis of Esophageal Squamous Cell Carcinoma.
- Ultrasound and CT-guided 125I implantation combined with TACE therapy in the treatment of recurrent HCC after RFA.
- Interventions to Reduce Fear of Cancer Recurrence Among People With Cancer: Scoping Review.